Symbols / IDYA Stock $27.60 -1.67% IDEAYA Biosciences, Inc.

Healthcare • Biotechnology • United States • NMS
IDYA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Yujiro S. Hata
Exch · Country NMS · United States
Market Cap 2.46B
Enterprise Value 1.82B
Income -140.06M
Sales 225.27M
FCF (ttm) -57.25M
Book/sh 10.67
Cash/sh 7.64
Employees 145
Insider 10d —
IPO May 23, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.40
PEG —
P/S 10.91
P/B 2.59
P/C —
EV/EBITDA -10.09
EV/Sales 8.10
Quick Ratio 10.45
Current Ratio 10.74
Debt/Eq 3.05
LT Debt/Eq —
EPS (ttm) -1.57
EPS next Y -3.73
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-05
Earnings (prior) 2026-05-05
ROA -10.76%
ROE -14.28%
ROIC —
Gross Margin -50.73%
Oper. Margin -16.55%
Profit Margin -62.17%
Shs Outstand 89.05M
Shs Float 87.01M
Insider Own 2.41%
Instit Own 110.12%
Short Float 15.23%
Short Ratio 14.31
Short Interest 11.34M
52W High 39.28
vs 52W High -29.74%
52W Low 20.50
vs 52W Low 34.63%
Beta -0.05
Impl. Vol. 40.54%
Rel Volume 1.33
Avg Volume 1.18M
Volume 1.56M
Target (mean) $51.69
Tgt Median $50.00
Tgt Low $36.00
Tgt High $66.00
# Analysts 16
Recom Strong_buy
Prev Close $28.07
Price $27.60
Change -1.67%
About

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$51.69
Mean price target
2. Current target
$27.60
Latest analyst target
3. DCF / Fair value
$-11.57
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$27.60
Low
$36.00
High
$66.00
Mean
$51.69

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-02 reit Wedbush Outperform → Outperform $58
2026-05-07 main Mizuho Outperform → Outperform $50
2026-04-14 main Goldman Sachs Neutral → Neutral $35
2026-04-14 main Wells Fargo Overweight → Overweight $48
2026-04-14 main RBC Capital Outperform → Outperform $53
2026-04-14 main Wedbush Outperform → Outperform $58
2026-04-14 main Guggenheim Buy → Buy $54
2026-03-31 reit Wedbush Outperform → Outperform $52
2026-02-19 main Citigroup Buy → Buy $65
2026-02-18 reit RBC Capital Outperform → Outperform $49
2026-02-18 reit Guggenheim Buy → Buy $50
2026-02-18 main Wedbush Outperform → Outperform $52
2026-01-21 main RBC Capital Outperform → Outperform $45
2026-01-06 main Truist Securities Buy → Buy $60
2025-11-24 init Truist Securities — → Buy $59
2025-11-11 main Mizuho Outperform → Outperform $46
2025-10-23 main JP Morgan Overweight → Overweight $79
2025-10-21 main Goldman Sachs Neutral → Neutral $30
2025-10-21 main RBC Capital Outperform → Outperform $41
2025-10-21 reit BTIG Buy → Buy $62
News
RSS: Latest IDYA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-02 STEIN JEFFREY Director — 50,000 $32.96 $1,647,890
2025-11-28 SNYDER DOUGLAS B General Counsel — 2,080 $16.91 $54,646
2025-11-28 RUIZ BRISENO ANDRES Officer — 1,935 $23.26 $60,492
2025-02-18 HATA YUJIRO S. Chief Executive Officer — 12,808 $19.52 $250,012
2024-06-27 THRONE JASON Officer — 53,484 $7.01 $415,587
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
218.71
+3024.43%
7.00
-70.07%
23.39
-54.08%
50.93
Operating Revenue
218.71
+3024.43%
7.00
-70.07%
23.39
-54.08%
50.93
Operating Expense
378.02
+13.19%
333.98
+111.63%
157.81
+39.13%
113.43
Research And Development
314.70
+6.80%
294.67
+127.53%
129.51
+44.64%
89.54
Selling General And Administration
63.32
+61.11%
39.30
+38.85%
28.31
+18.45%
23.90
General And Administrative Expense
63.32
+61.11%
39.30
+38.85%
28.31
+18.45%
23.90
Other Gand A
63.32
+61.11%
39.30
+38.85%
28.31
+18.45%
23.90
Total Expenses
378.02
+13.19%
333.98
+111.63%
157.81
+39.13%
113.43
Operating Income
-159.31
+51.28%
-326.98
-143.23%
-134.43
-115.08%
-62.50
Total Operating Income As Reported
-159.31
+51.28%
-326.98
-143.23%
-134.43
-115.08%
-62.50
EBITDA
-154.72
+52.12%
-323.14
-147.77%
-130.42
-121.10%
-58.99
Normalized EBITDA
-154.72
+52.12%
-323.14
-147.77%
-130.42
-121.10%
-58.99
Reconciled Depreciation
4.59
+19.80%
3.83
-4.34%
4.01
+14.03%
3.52
EBIT
-159.31
+51.28%
-326.98
-143.23%
-134.43
-115.08%
-62.50
Net Income
-113.70
+58.58%
-274.48
-142.98%
-112.96
-92.59%
-58.66
Pretax Income
-113.70
+58.58%
-274.48
-142.98%
-112.96
-92.59%
-58.66
Net Non Operating Interest Income Expense
45.62
-13.11%
52.50
+144.54%
21.47
+458.05%
3.85
Net Interest Income
45.62
-13.11%
52.50
+144.54%
21.47
+458.05%
3.85
Interest Income Non Operating
45.62
-13.11%
52.50
+144.54%
21.47
+458.05%
3.85
Interest Income
45.62
-13.11%
52.50
+144.54%
21.47
+458.05%
3.85
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-113.70
+58.58%
-274.48
-142.98%
-112.96
-92.59%
-58.66
Net Income From Continuing Operation Net Minority Interest
-113.70
+58.58%
-274.48
-142.98%
-112.96
-92.59%
-58.66
Net Income From Continuing And Discontinued Operation
-113.70
+58.58%
-274.48
-142.98%
-112.96
-92.59%
-58.66
Net Income Continuous Operations
-113.70
+58.58%
-274.48
-142.98%
-112.96
-92.59%
-58.66
Normalized Income
-113.70
+58.58%
-274.48
-142.98%
-112.96
-92.59%
-58.66
Net Income Common Stockholders
-113.70
+58.58%
-274.48
-142.98%
-112.96
-92.59%
-58.66
Otherunder Preferred Stock Dividend
—
—
—
2.16
Diluted EPS
-1.28
+61.90%
-3.36
-71.43%
-1.96
-38.03%
-1.42
Basic EPS
-1.28
+61.90%
-3.36
-71.43%
-1.96
-38.03%
-1.42
Basic Average Shares
88.49
+8.33%
81.68
+42.00%
57.52
+38.79%
41.44
Diluted Average Shares
88.49
+8.33%
81.68
+42.00%
57.52
+38.79%
41.44
Diluted NI Availto Com Stockholders
-113.70
+58.58%
-274.48
-142.98%
-112.96
-92.59%
-58.66
Line Item Trend 2023-12-31
Total Assets
649.32
Current Assets
532.63
Cash Cash Equivalents And Short Term Investments
525.11
Cash And Cash Equivalents
157.02
Other Short Term Investments
368.10
Receivables
0.02
Accounts Receivable
0.02
Other Receivables
—
Prepaid Assets
—
Other Current Assets
7.50
Total Non Current Assets
116.68
Net PPE
8.41
Gross PPE
18.02
Accumulated Depreciation
-9.61
Properties
0.00
Machinery Furniture Equipment
1.00
Other Properties
13.70
Leases
3.32
Investments And Advances
107.49
Other Non Current Assets
0.78
Total Liabilities Net Minority Interest
28.23
Current Liabilities
27.10
Payables And Accrued Expenses
25.35
Payables
6.60
Accounts Payable
6.60
Current Accrued Expenses
18.76
Current Debt And Capital Lease Obligation
1.75
Current Capital Lease Obligation
1.75
Current Deferred Liabilities
0.00
Current Deferred Revenue
0.00
Total Non Current Liabilities Net Minority Interest
1.12
Long Term Debt And Capital Lease Obligation
1.12
Long Term Capital Lease Obligation
1.12
Non Current Deferred Liabilities
0.00
Non Current Deferred Revenue
0.00
Stockholders Equity
621.09
Common Stock Equity
621.09
Capital Stock
0.01
Common Stock
0.01
Preferred Stock
0.00
Share Issued
65.04
Ordinary Shares Number
65.04
Treasury Shares Number
0.00
Additional Paid In Capital
968.88
Retained Earnings
-348.36
Gains Losses Not Affecting Retained Earnings
0.56
Other Equity Adjustments
0.56
Total Equity Gross Minority Interest
621.09
Total Capitalization
621.09
Working Capital
505.53
Invested Capital
621.09
Total Debt
2.87
Capital Lease Obligations
2.87
Net Tangible Assets
621.09
Tangible Book Value
621.09
Available For Sale Securities
107.49
Investmentin Financial Assets
107.49
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-71.10
+71.28%
-247.58
-114.87%
-115.22
-32.18%
-87.17
Cash Flow From Continuing Operating Activities
-71.10
+71.28%
-247.58
-114.87%
-115.22
-32.18%
-87.17
Net Income From Continuing Operations
-113.70
+58.58%
-274.48
-142.98%
-112.96
-92.59%
-58.66
Depreciation Amortization Depletion
4.59
+19.80%
3.83
-4.34%
4.01
+14.03%
3.52
Depreciation
4.59
+19.80%
3.83
-4.34%
4.01
+14.03%
3.52
Depreciation And Amortization
4.59
+19.80%
3.83
-4.34%
4.01
+14.03%
3.52
Stock Based Compensation
46.12
+32.72%
34.75
+87.93%
18.49
+58.99%
11.63
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
1.87
-83.82%
11.55
+187.42%
-13.21
+69.26%
-42.97
Change In Receivables
0.00
0.00
-100.00%
0.19
-78.36%
0.89
Changes In Account Receivables
0.00
0.00
-100.00%
0.19
-78.36%
0.89
Change In Prepaid Assets
-7.84
-27.29%
-6.16
-201.17%
-2.04
+3.49%
-2.12
Change In Payables And Accrued Expense
13.12
-31.19%
19.07
+346.70%
4.27
-33.65%
6.44
Change In Accrued Expense
10.43
-3.40%
10.79
+560.18%
1.64
-64.24%
4.57
Change In Payable
2.70
-67.43%
8.28
+214.23%
2.63
+41.36%
1.86
Change In Account Payable
2.70
-67.43%
8.28
+214.23%
2.63
+41.36%
1.86
Change In Other Working Capital
-5.97
—
-13.75
+70.41%
-46.48
Change In Other Current Assets
—
—
—
1.41
Change In Other Current Liabilities
2.56
+286.78%
-1.37
+26.87%
-1.87
-10.18%
-1.70
Investing Cash Flow
69.98
+113.92%
-502.56
-217.16%
-158.46
-374.36%
-33.40
Cash Flow From Continuing Investing Activities
69.98
+113.92%
-502.56
-217.16%
-158.46
-374.36%
-33.40
Net PPE Purchase And Sale
-2.37
+38.61%
-3.86
-62.88%
-2.37
+31.22%
-3.44
Purchase Of PPE
-2.37
+38.61%
-3.86
-62.88%
-2.37
+31.22%
-3.44
Capital Expenditure
-2.37
+38.61%
-3.86
-62.88%
-2.37
+31.22%
-3.44
Net Investment Purchase And Sale
72.34
+114.51%
-498.70
-219.50%
-156.09
-420.97%
-29.96
Purchase Of Investment
-607.89
+48.97%
-1,191.31
-99.89%
-595.98
-132.98%
-255.81
Sale Of Investment
680.23
-1.79%
692.61
+57.45%
439.89
+94.77%
225.85
Financing Cash Flow
29.78
-95.60%
677.55
+86.80%
362.72
+273.30%
97.17
Cash Flow From Continuing Financing Activities
29.78
-95.60%
677.55
+86.80%
362.72
+273.30%
97.17
Net Common Stock Issuance
24.86
-96.20%
654.23
+111.20%
309.76
+226.20%
94.96
Proceeds From Stock Option Exercised
4.92
-78.89%
23.32
-55.96%
52.95
+2303.72%
2.20
Changes In Cash
28.66
+139.48%
-72.59
-181.53%
89.04
+480.27%
-23.41
Beginning Cash Position
85.18
-46.01%
157.78
+129.53%
68.74
-25.41%
92.15
End Cash Position
113.84
+33.64%
85.18
-46.01%
157.78
+129.53%
68.74
Free Cash Flow
-73.47
+70.78%
-251.44
-113.82%
-117.59
-29.77%
-90.62
Interest Paid Supplemental Data
0.00
-100.00%
0.03
-63.77%
0.07
+15.00%
0.06
Income Tax Paid Supplemental Data
—
—
0.00
0.00
Amortization Of Securities
-9.98
+57.06%
-23.23
-101.10%
-11.55
-1562.30%
-0.69
Common Stock Issuance
24.86
-96.20%
654.23
+111.20%
309.76
+226.20%
94.96
Issuance Of Capital Stock
24.86
-96.20%
654.23
+111.20%
309.76
+226.20%
94.96
Net Preferred Stock Issuance
—
9.40
-77.72%
42.18
0.00
Preferred Stock Issuance
—
9.40
-77.72%
42.18
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category